

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A method for treating an angiogenesis-dependent disease in a mammal in need thereof comprising administering to the mammal an EMMPRIN monoclonal antibody or fragment thereof in an amount effective to inhibit angiogenesis in said mammal, wherein the angiogenesis-dependent disease is cancer.
2. (Cancelled)
3. (Previously Presented) The method according to claim 1, in which the antibody fragment is an Fab, Fab', or F(ab')2 fragment.
4. (Previously Presented) The method according to claim 1, in which the monoclonal antibody is administered intravenously.
5. (Previously Presented) The method according to claim 1, in which the monoclonal antibody is administered in the amount of from 0.05 mg/kg to 12.0 mg/kg body weight.
6. (Previously Presented) The method according to claim 1, in which the monoclonal antibody is administered in a bolus dose followed by an infusion of said antibody.
7. (Previously Presented) The method according to claim 1, in which the mammal is a human patient.
8. (Cancelled)
9. (Previously Presented) The method according to claim 1, wherein the angiogenesis-dependent disease is a disease selected from the group consisting of angioma and angiofibroma.
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Currently Amended) A method for inhibiting tumor growth in a mammal in need thereof comprising administering to the mammal an EMMPRIN antagonist monoclonal antibody or fragment thereof in an amount effective to inhibit angiogenesis of the vasculature supporting the growth of said tumor.
14. (Previously Presented) A method for treating tumor growth in a mammal in need thereof comprising administering to the mammal an EMMPRIN monoclonal antibody or fragment thereof in an amount effective to inhibit angiogenesis of the vasculature supporting the growth of said tumor.

15. (Previously Presented) A method for treating metastases in a mammal in need thereof comprising administering to the mammal an EMMPRIN monoclonal antibody in an amount effective treat metastases in said mammal.
16. (Previously Presented) A method of any of claims 1, or 13, wherein the EMMPRIN monoclonal antibody or fragment thereof is administered in combination with a second anti-angiogenic agent.
17. (Previously Presented) A method of claim 16 where the second anti-angiogenic agent is a Mab capable of specifically binding the adhesion molecules containing alphaV.
18. (Cancelled)